Search Results - LÜdtke-Heckenkamp, Kerstin

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
    The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

    The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized t... by Nitz, Ulrike, Gluz, Oleg, Kreipe, Hans H., Christgen, Matthias, Kuemmel, Sherko, Baehner, Frederick L., Shak, Steven, Aktas, Bahriye, Braun, Michael, Lüdtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Nuding, Benno, Darsow, Maren, Schumacher, Claudia, Krauss, Katja, Malter, Wolfram, Thill, Marc, Warm, Mathias, Wuerstlein, Rachel, Kates, Ronald E., Harbeck, Nadia

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study

    Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study by Lück, Hans-Joachim, Schmidt, Marcus, Hesse, Tobias, Hoffmann, Oliver, Heinrich, Bernhard J, Park-Simon, Tjoung-Won, Grischke, Eva-Maria, Weide, Rudolf, Müller-Huesmann, Harald, Lüdtke-Heckenkamp, Kerstin, Fischer, Dorothea, Zemlin, Cosima, Kögel, Matthias, Wu, Jane, Schmitz, Helga, Engelbrecht, Christian, Jackisch, Christian

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  3. 3
    Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)

    Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase... by Decker, Thomas, Lüdtke-Heckenkamp, Kerstin, Melnichuk, Luidmila, Hirmas, Nader, Lübbe, Kristina, Zahn, Mark-Oliver, Schmidt, Marcus, Denkert, Carsten, Lorenz, Ralf, Müller, Volkmar, Zahm, Dirk-Michael, Mundhenke, Christoph, Bauer, Stefan, Thill, Marc, Seropian, Peter, Filmann, Natalie, Loibl, Sibylle

    Published in Breast (Edinburgh)
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients

    Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients by Wuerstlein, Rachel, Harbeck, Nadia, Grischke, Eva-Maria, Forstmeyer, Dirk, von Schumann, Raquel, Krabisch, Petra, Lüdtke-Heckenkamp, Kerstin, Stefek, Andrea, Stoetzer, Oliver, Grafe, Andrea, Kaltenecker, Gabriele, Forstbauer, Helmut, Augustin, Doris, Schrader, Iris, Tio, Joke, Nitz, Ulrike, Gluz, Oleg, Kates, Ronald E., Graeser, Monika Karla

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin ® ) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin)

    Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin ® ) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS He... by Schmidt, Marcus, KÜmmel, Sherko, Ruf-Doerdelmann, Antonia, Distelrath, Andrea, Wacker, JÜrgen, Schmatloch, Sabine, Busch-Liles, Saskia, LÜdtke-Heckenkamp, Kerstin

    Published in Anticancer research
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    Abstract PS10-16: Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study

    Abstract PS10-16: Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive,... by Wöckel, Achim, Brucker, Cosima, Decker, Thomas, Falbrede, Jörg, Forstbauer, Helmut, Göhler, Thomas, Hoffmann, Oliver, Jackisch, Christian, Janssen, Jan, Köhler, Andreas, Lüdtke-Heckenkamp, Kerstin, Lüftner, Diana, Marmé, Frederik, Nusch, Arnd, Reimer, Toralf, Roos, Christian, Schmidt, Marcus, Weide, Rudolf, Fasching, Peter

    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Abstract P1-18-15: Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) locally advanced or metastatic breast cancer: Fourth interim analysis from the RIBANNA study

    Abstract P1-18-15: Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with hormone rece... by Lüftner, Diana, Brucker, Cosima, Decker, Thomas, Fasching, Peter, Göhler, Thomas, Jackisch, Christian, Janssen, Jan, Köhler, Andreas, Lüdtke-Heckenkamp, Kerstin, van Mackelenbergh, Marion, Marmé, Frederik, Nusch, Arnd, Rautenberg, Beate, Reimer, Toralf, Schmidt, Marcus, Weide, Rudolf, Wimberger, Pauline, Nabieva, Naiba, Roos, Christian, Wöckel, Achim

    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Abstract P1-19-33: Real-world efficacy of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Second interim analysis from the RIBANNA study

    Abstract P1-19-33: Real-world efficacy of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positi... by Wöckel, Achim, Basiora, Pawel, Bohlmann, Michael, Decker, Thomas, Falbrede, Jörg, Fasching, Peter, Forstbauer, Helmut, Hesse, Tobias, Hoffmann, Oliver, Jackisch, Christian, Kaczerowsky, Anna, Lorenz, Ralf, Lüdtke-Heckenkamp, Kerstin, Lüftner, Diana, Marmé, Frederik, Mueller, Thomas, Mundhenke, Christoph, Nusch, Arnd, Petersen, Volker, Prange-Krex, Gabriele, Reimer, Toralf, Resch, Thomas, Roos, Christian, Tomé, Oliver, Weishap, Anja

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  9. 9
    Abstract P3-01-09: Maintenance Therapy with ET and Ribociclib after 1st line Chemotherapy (CT) in Hormone Receptor (HR)-positive/HER2-negative Metastatic Breast Cancer (BC): a Phase II Trial (AMICA)

    Abstract P3-01-09: Maintenance Therapy with ET and Ribociclib after 1st line Chemotherapy (CT) in Hormone Receptor (HR)-positive/HER2-negative Metastatic Breast Cancer (BC): a Phas... by Decker, Thomas, Lüdtke-Heckenkamp, Kerstin, Melnichuk, Luidmila, Furlanetto, Jenny, Lübbe, Kristina, Zahn, Mark-Oliver, Schmidt, Marcus, Denkert, Carsten, Lorenz, Ralf, Müller, Volkmar, Zahm, Dirk-Michael, Mundhenke, Christoph, Bauer, Stefan, Thill, Marc, Seropian, Peter, Filmann, Natalie, Loibl, Sibylle

    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Abstract P4-01-01: RIBANNA 5th interim analysis: Matched-pair analysis of progression-free survival (PFS) across treatment cohorts and comparison of frontline ribociclib + endocrine therapy PFS data from RIBANNA vs MONALEESA trials, in HR+, HER2– ABC

    Abstract P4-01-01: RIBANNA 5th interim analysis: Matched-pair analysis of progression-free survival (PFS) across treatment cohorts and comparison of frontline ribociclib + endocrin... by Jackisch, Christian, Brucker, Cosima, Decker, Thomas, Engel, Anne, Fasching, Peter A., Göhler, Thomas, Janssen, Jan, Köhler, Andreas, Lüdtke-Heckenkamp, Kerstin, Lüftner, Diana, van Mackelenbergh, Marion, Marmé, Frederik, Nusch, Arnd, Rautenberg, Beate, Reimer, Toralf, Schmidt, Marcus, Weide, Rudolf, Wimberger, Pauline, Roos, Christian, Wöckel, Achim

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  11. 11
    Abstract P4-01-03: Progression-free survival and patient-reported outcomes in HR+, HER2– ABC patients treated with first-line ribociclib + endocrine therapy (ET) or ET monotherapy or chemotherapy in real world setting: 5th interim analysis of RIBANNA

    Abstract P4-01-03: Progression-free survival and patient-reported outcomes in HR+, HER2– ABC patients treated with first-line ribociclib + endocrine therapy (ET) or ET monotherapy... by Fasching, Peter A., Brucker, Cosima, Decker, Thomas, Engel, Anne, Göhler, Thomas, Jackisch, Christian, Janssen, Jan, Köhler, Andreas, Lüdtke-Heckenkamp, Kerstin, Lüftner, Diana, van Mackelenbergh, Marion, Marmé, Frederik, Nusch, Arnd, Rautenberg, Beate, Reimer, Toralf, Schmidt, Marcus, Weide, Rudolf, Wimberger, Pauline, Roos, Christian, Wöckel, Achim

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: